MICHAEL AURIGEMA: Open Payments
NPI 1548972375 · NORFOLK, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,441 in 81 payments from 10 companies in 2025. Trend: 2023 $96 · 2024 $664 · 2025 $1,441
Food & beverage: $1,441
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 43 | $618 |
| Janssen Pharmaceuticals, Inc | 7 | $190 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $181 |
| Braeburn Inc. | 9 | $145 |
| E.R. Squibb & Sons, L.L.C. | 6 | $135 |
| Gilead Sciences, Inc. | 3 | $69 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Alkermes, Inc. | 1 | $26 |
| Indivior Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
Products named: VRAYLAR, CAPLYTA, BRIXADI, COBENFY, INVEGA SUSTENNA, SPRAVATO, MAVYRET, REXULTI.
Industry payments across VA — which companies pay providers there.
